Dysregulation of macrophage PEPD in obesity determines adipose tissue fibro-inflammation and insulin resistance
Publication: Nature
V. Pellegrinelli, S. Rodriguez-Cuenca, C. Rouault, E. Figueroa-Juarez, H. Schilbert, S. Virtue, J. M. Moreno-Navarrete, G. Bidault, M. C. Vázquez-Borrego, A. R. Dias, B. Pucker, M. Dale, M. Campbell, S. Carobbio, Y. H. Lin, M. Vacca, J. Aron-Wisnewsky, S. Mora, M. M. Masiero, A. Emmanouilidou, S. Mukhopadhyay, G. Dougan, M. den Hoed, R. J. F. Loos, J. M. Fernández-Real, D. Chiarugi, K. Clément & A. Vidal-Puig
25 April 2022
Summary
New research shows that an enzyme produced by macrophages (immune system cells) in fat tissue plays an essential role in the loss of metabolic health in people with obesity and might serve as a biomarker to help us identify those at the highest risk of fibrosis, inflammation and insulin resistance or type 2 diabetes associated with obesity. It also identifies a potential target for drugs that might prevent or reverse metabolic disease and could throw light on a long-unexplained paradox. Read more.